Group 1 - Generate Biomedicines (GENB) priced its IPO at the midpoint [2] - One IPO and six SPACs came to market in the past week [2] - A major issuer joined the pipeline as February comes to a close [2]

Company Overview - Generate Biomedicines, backed by Flagship, experienced a 6.25% decline in its share price during its Nasdaq debut, resulting in a valuation of $1.91 billion [1]. Market Context - The decline in Generate Biomedicines' shares is attributed to ongoing market volatility, which has made investors cautious regarding new listings [1].

Group 1 - APEX Tech Acquisition, TRG Latin America Acquisitions, and Fortress Value Acquisition V collectively raised $550 million in the US stock market on February 26, 2026 [1][2] - APEX Tech Acquisition, led by Shaoren Liu from China, targets US companies with no industry restrictions, focusing on cash flow, technological leadership, and management teams [2] - TRG Latin America Acquisitions, initiated by Nicolas Rohatyn, focuses on growth sectors in Latin America, particularly Argentina, targeting energy, mining, agriculture, and technology [2] - Fortress Value Acquisition V, led by Andrew McKnight, has no geographic or industry restrictions and aims to find companies that can provide attractive risk-adjusted returns [2] Group 2 - Generate Biomedicines plans to raise $400 million by issuing 25 million shares at $16 each, with the funds allocated for clinical trials, platform innovation, candidate drug development, and general corporate purposes [4] - Generate Biomedicines is a tech-driven biopharmaceutical company utilizing an AI platform to design, test, and advance new drug candidates to address biological challenges that traditional technologies struggle with [4] - Projected revenues for Generate Biomedicines are $20.46 million and $31.89 million for 2024 and 2025, respectively, with corresponding net losses of $181 million and $223 million [4]

公司宣称其技术潜力已获得初步验证，三款通过计算工程技术开发的蛋白质药物已进入人体临床试验阶 段。其中进度最快的GB-0895是一款研究性长效抗胸腺基质淋巴细胞生成素单克隆抗体，目前正在重症 哮喘适应症的注册性临床三期试验中招募患者。 Generate Biomedicines计划以股票代码"GENB"于今晚在纳斯达克挂牌上市。高盛、摩根士丹利、Piper Sandler、古根海姆证券及Cantor Fitzgerald担任本次发行的联合账簿管理人。 据公司介绍，其人工智能驱动的Generate平台构建了一个紧密整合的"设计-构建-测试-学习"闭环系统， 旨在生成具有治疗价值的专有数据并开发差异化分子解决方案。 专注于免疫学与肿瘤学领域的AI药物研发公司Generate Biomedicines(GENB.US)正式公布美股IPO发行 价。这家处于临床三期阶段的生物科技公司以每股16美元(位于15至17美元定价区间中点)发行2500万 股，成功募资4亿美元。 ...

Company Overview - Generate Biomedicines has successfully raised $400 million through its U.S. initial public offering (IPO) by pricing shares at $16 each [1]. Financial Highlights - The IPO raised a total of $400 million, indicating strong investor interest in the company's drug development capabilities [1].

Core Viewpoint - Generate Biomedicines, Inc. has announced the pricing of its initial public offering (IPO) at $16.00 per share, aiming to raise gross proceeds of $400 million before expenses [1] Group 1: IPO Details - The company is offering 25,000,000 shares of common stock in the IPO [1] - Underwriters have a 30-day option to purchase an additional 3,750,000 shares at the IPO price [1] - Trading on the Nasdaq Global Select Market is expected to commence on February 27, 2026, under the ticker symbol "GENB" [1] Group 2: Financial Management - Goldman Sachs & Co. LLC and Morgan Stanley are serving as joint lead book-running managers for the offering [1] - Other book-running managers include Piper Sandler, Guggenheim Securities, and Cantor [1] Group 3: Regulatory Information - A registration statement for the securities was filed and declared effective by the U.S. Securities and Exchange Commission on February 26, 2026 [1] - The offering is being conducted solely through a prospectus [1]

Company Overview - Generate Biomedicines, a drug developer based in Somerville, Massachusetts, is targeting a valuation of up to $2.17 billion in its upcoming initial public offering (IPO) in the United States [1] - The company is backed by venture firm Flagship Pioneering and aims to raise up to $425 million by offering 25 million shares priced between $15 and $17 each [1] IPO Details - Generate Biomedicines plans to list on the Nasdaq under the symbol "GENB" [1] - The IPO comes as biotech offerings have seen a strong start this year, following a sluggish 2025, attributed to easing interest rates and increased capital inflows into the sector [1] Underwriters - The underwriters for the offering include Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor [1]

As filed with the Securities and Exchange Commission on February 23, 2026. Registration No. 333-293204 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Generate Biomedicines, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1630228 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 101 South Street, Suite 9 ...

Group 1 - The IPO market is showing resilience amid recent volatility, with one small issuer and four blank check companies going public this past week [2] - Rank One Computing, a provider of facial recognition software, successfully upsized and priced its IPO [2]

WASHINGTON, D.C. 20549 As filed with the Securities and Exchange Commission on February 13, 2026. Registration No. 333-293204 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Amendment No. 1 THE SECURITIES ACT OF 1933 Generate Biomedicines, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 83-1630228 (Primary Standard Industrial Classification Code Number) 101 South Street, Suite 900 Somerville, MA 02143 (I.R.S. Employer ...